Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03949933
Recruitment Status : Not yet recruiting
First Posted : May 14, 2019
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
Guoliang Jiang, Shanghai Proton and Heavy Ion Center

Brief Summary:
The aim of this study is to evaluate the toxicity and tolerance of proton and carbon ion radiotherapy (PCRT) for locally advanced pancreatic carcinoma (LAPC)

Condition or disease Intervention/treatment Phase
Pancreatic Carcinoma Radiation: proton and carbon ion radiotherapy Not Applicable

Detailed Description:
The proton dose of 50.4GyE in 28 fractions was delivered to clinical target volume (CTV), and carbon ion as a boost dose to gross tumor volume (GTV) escalated from 12GyE to 18GyE with 3GyE per fraction in 3 dose levels. The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were the endpoints.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial of Proton and Carbon Ion Radiation Dose Escalation in Patients With Locally Advanced Pancreatic Cancer
Estimated Study Start Date : May 7, 2019
Estimated Primary Completion Date : May 31, 2019
Estimated Study Completion Date : May 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: proton and carbon ion radiotherapy
proton and carbon ion radiotherapy
Radiation: proton and carbon ion radiotherapy
proton and carbon ion radiotherapy




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Time interval from the start of radiotherapy to 3 months after the completion of radiotherapy ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0


Secondary Outcome Measures :
  1. overall survival rate [ Time Frame: 2 years ]
    overall survival rate

  2. local progression-free survival [ Time Frame: 2 years ]
    local progression-free survival

  3. progression-free survivals [ Time Frame: 2 years ]
    progression-free survivals



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The histologically or cytologically confirmed, or the clinically diagnosed by clinical diagnosis criterion proposed by Pancreatic Cancer Committee of Chinese Anti-Cancer Association [15], which was based on evidences of (1). Typical symptoms of abdominal and/or back pain; (2). CA19-9 increased over the normal up limit; (3). A pancreatic mass shown on CT or MRI; and (4). SUV of PET-CT in mass increased compared to that in normal pancreas;
  2. Unresectable LAPC defined by the criteria of (NCCN) guidelines (Version 1. 2013), or refusal to surgery;
  3. Gastrointestinal tract (GI) not invaded;
  4. ECOG Performance Status 0-1 within 30 days prior to registration;
  5. Age of ≥ 18 years old;
  6. Enough hematological function (white blood cell count ≥ 3.0×109/L; platelets ≥50×109/L; hemoglobin ≥ 90 g/L);
  7. Enough liver and kidney functions (creatinine <110gmol/L; urea nitrogen <7.1mmol/L; bilirubin < 1.5 x ULN, ALT and AST ≤ 2.5 x ULN);
  8. No evidence of distant metastases, based upon PET, CT, or MRI images of the chest, abdomen and pelvis within 30 days prior to registration;
  9. Informed consent form obtained.

Exclusion Criteria:

  1. No pathological evidence of malignant tumor;
  2. ECOG>=2;
  3. Liver, kidney and bone marrow function are poor and not adequate for treatment;
  4. Side effect of previous treatment is not covered yet, eg. The interval between TACE and other anti-tumor therapy is less than one month;
  5. Prior radiation therapy to the abdomen or radioactive particle implantation;
  6. cardiac pacemaker or other metal implantation whose function may be disturbed by high energy beam or which affect the dose in target volume;
  7. Dose constrain of normal liver, digested system and other OAR could not reach the expecting safe dose constrain;
  8. The patient could not get benefit from proton or heavy ion radiotherapy in physician's opinion;
  9. Comitant diseases or affecters which could affect the proton or heavy ion radiotherapy;
  10. Pregnancy(blood or urine β-HCG certified)or lactation;
  11. Drug or alcohol abused;
  12. HIV positive, including received anti-retrovirus treatment; chronic hepatitis B virus replication stage; hepatitis C active stage; syphilis active stage;
  13. HBV positive, hepatitis B virus replication stage, need to be treated with anti-virus treatment, but could not receive anti-virus treatment because of comitant disease;
  14. Psychiatric history, possibly affecting the completion of treatment;
  15. patients with serious complications that might affect radiotherapy, including 1)unstable angina pectoris requiring hospitalization in the last 6 months,congestive heart failure,myocardial infarction; 2)acute bacterial or systemic fungal infections; 3)exacerbation of chronic obstructive pulmonary disease ( COPD) or other respiratory system disease requiring hospitalization 4)hepatic function insufficiency or renal function insufficiency 5) immunosuppressed patients
  16. patients with connective tissue disease such as active scleroderma or lupus and so on, which is contraindication for radiotherapy
  17. patients can't understand treatment goal or unwilling/unable to sign up inform consent form;
  18. no civil capability or limited civil capacity.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03949933


Contacts
Layout table for location contacts
Contact: zheng wang, Dr. +862138296666 zheng.wang@sphic.org.cn
Contact: Zhan Yu, Dr. +862138296666 zhan.yu@sphic.org.cn

Sponsors and Collaborators
Shanghai Proton and Heavy Ion Center
Investigators
Layout table for investigator information
Principal Investigator: guoliang Jiang, Dr. Shanghai Proton and Heavy Ion Center

Layout table for additonal information
Responsible Party: Guoliang Jiang, director of clinical technical committee, professor, Shanghai Proton and Heavy Ion Center
ClinicalTrials.gov Identifier: NCT03949933     History of Changes
Other Study ID Numbers: SPHIC-TR-PaCa2015-10
First Posted: May 14, 2019    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Guoliang Jiang, Shanghai Proton and Heavy Ion Center:
proton and carbon ion radiotherapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases